Evidence guide · South Africa
GHK-Cu copper peptide: what the evidence shows for skin, hair and injections
GHK-Cu has decades of lab research but only two randomised trials in people in a 2026 review. What copper-peptide serums can do, why the hair data are for blends, and why injections carry FDA safety flags.
Review type: research summary. This page summarises published research and product labels, cited below.
GHK-Cu, often sold as "copper peptide" and listed on skincare labels as copper tripeptide-1, is a small three-amino-acid peptide (glycine, histidine and lysine) bound to copper. It turns up in two very different places: in serums and creams for wrinkles and hair, and as an injectable peptide marketed directly to patients. Its evidence is now being argued over in print. A team led from Dubai Health, with co-authors in the US and Egypt, published a systematic review in Aesthetic Surgery Journal in August 2026, a letter in the same journal on 4 November 2026 was titled "Mechanistic plausibility should not be conflated with clinical validation" of GHK-Cu, and the authors' response appeared on 10 November.
Short answer: the lab and animal research is extensive, but the human evidence is thin. The August 2026 review found only two randomised controlled trials in people, and its authors say well-designed clinical trials are few. The published trials are small: one, using a serum supplied by its maker, found less wrinkle depth and volume over eight weeks, and another found no objective benefit after laser resurfacing. A copper-peptide serum is a low-stakes cosmetic experiment with modest expectations. Injecting GHK-Cu is a different matter: the US Food and Drug Administration (FDA) lists injectable GHK-Cu among compounding substances that may present significant safety risks, citing limited human safety data. Skip the injections.
Why people are interested
GHK occurs naturally in the human body. A 2018 review by Loren Pickart and Anna Margolina describes GHK increasing collagen, elastin and glycosaminoglycan production, supporting skin fibroblasts and improving tissue repair in several tissues, and suggests that gene-expression data may explain these varied effects. A 2026 review describes more than four decades of preclinical evidence for tissue regeneration, anti-inflammatory and antioxidant effects, but says the clinical literature in humans remains thin and fragmented. Preclinical findings explain why the molecule is interesting; they do not show what a cream or an injection does in people.
What the human trials show
The August 2026 Aesthetic Surgery Journal review searched PubMed, Embase and Cochrane CENTRAL to March 2026 and included 20 studies of GHK-Cu used on its own for aesthetic purposes. Eighteen were preclinical. Only two were randomised controlled trials in people. It reports that GHK-Cu improved patient-reported satisfaction after laser resurfacing and reduced wrinkle volume and depth compared with controls. The authors say GHK-Cu has a reasonable biological basis, but that the findings were limited by methodological variability and few well-designed clinical trials, and that larger controlled trials with standard formulations and doses are needed. Two small published randomised trials show what the human evidence looks like.
- Wrinkle serum trial (2016): 40 women aged 40 to 65 applied products twice a day for eight weeks, with a different product on each side of the face, in a randomised, double-blind design run by Dermatest, a German cosmetic research institute, with University of Auckland researchers. Against the plain serum base, wrinkle volume changed by -24.1% ± 8.6 with the GHK-Cu serum and -15.0% ± 5.2 with the base, and wrinkle depth by -20.3% ± 8.7 versus -15.3% ± 7.2. The authors report that as a 55.8% relative reduction in wrinkle volume and a 32.8% decrease in wrinkle depth. The serum decreased wrinkle volume by 31.6% more than a commercial product containing Matrixyl 3000, another peptide ingredient. The GHK-Cu serum and the serum base were supplied by the New Zealand skincare company Snowberry. One participant stopped after minor skin reactions to two of the products.
- Laser resurfacing trial (2006): 13 patients who completed the study had laser treatment around the mouth and were randomised to aftercare with or without GHK-Cu products. Blinded evaluators and computer analysis found no significant difference between groups in redness during recovery, or in wrinkles or overall skin quality at 12 weeks. Patients using GHK-Cu rated the improvement in their skin quality higher (p = 0.04).
A separate 2026 review in Archives of Internal Medicine Research reached the same conclusion: the human evidence is a handful of small trials and case series, mostly of cosmetic creams. It notes that two frequently cited 2002 trials of GHK-Cu face and eye creams were published only as conference abstracts, never as full peer-reviewed papers. It also describes a 2025 split-face study in acne scars in which GHK-Cu serum added to dermaroller treatment showed early improvement but no significant difference by week 16, with the authors flagging a risk of skin darkening (hyperpigmentation) in the GHK-Cu arm.
Hair
A systematic review published in the Journal of Drugs in Dermatology on 1 November 2026 found 14 clinical trials of peptide-containing products for hair loss. It gave a grade B recommendation to formulations containing acetyl tetrapeptide-3, biotinoyl tripeptide-1, a glycyl-histidyl-lysine (GHK) peptide and the penta-peptide Gly-Pro-Ile-Gly-Ser. It described combinations containing acetyl tetrapeptide-3, biotinoyl tripeptide-1 and the GHK peptide as effective and well tolerated. That supports some multi-ingredient peptide hair products, not GHK-Cu on its own. In the US, the FDA says a claim that a product will restore hair growth makes it a drug, even if it is sold as a cosmetic.
Injectable GHK-Cu
The FDA lists GHK-Cu for injectable routes among bulk drug substances that may present significant safety risks in compounding, saying compounded injectable GHK-Cu may pose a risk of immune reactions because of aggregation and peptide-related impurities, and that there are limited data in humans to inform safety. The interim US policy announced on 30 October 2026 by the Department of Health and Human Services covers six peptides for compounding (BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500), and GHK-Cu is not one of them. A 2026 review in Sports Medicine lists GHK-Cu among unapproved peptides marketed directly to patients, and says rigorous human safety data for many unapproved peptides are scarce, with potential for serious harm.
Our view
- The gap between the lab and the clinic is the story. GHK-Cu has decades of preclinical research but only two randomised trials in people in the August 2026 review, and the published skin trials are small, one using products supplied by the maker and one negative on objective measures.
- A copper-peptide serum is a reasonable thing to try if you like the product, but judge it as a cosmetic and expect modest changes at best.
- Do not inject GHK-Cu. Injectable versions have limited human safety data, and immune reactions linked to impurities and aggregation are the specific risks the FDA names.
- Be sceptical of hair claims for GHK-Cu alone. The better hair data are for multi-peptide formulations, and the evidence is still graded B, not A.
- Stop a product that irritates or darkens your skin, and ask a dermatologist or pharmacist before using copper-peptide products after a skin procedure.
South African rules
SAHPRA warns about the growing sale of unregistered peptide products promoted for uses including anti-ageing, muscle growth and injury recovery, sold through online platforms, social media, gyms, wellness centres and informal suppliers. Its list of examples names other peptides, not GHK-Cu, but its rule is general: under the Medicines and Related Substances Act 101 of 1965, any product intended to treat, prevent or alter bodily functions must be registered with SAHPRA before it can be sold. SAHPRA lists infections from injectable use and contaminated or counterfeit products among the risks, and warns against self-administration without medical supervision. Report side effects to adr@sahpra.org.za.
FAQ
What is GHK-Cu?
A tripeptide made of glycine, histidine and lysine bound to copper. It occurs naturally in the body and is used in skincare as copper tripeptide-1.
Does copper peptide skincare work?
There is some evidence. One small, product-supplied eight-week trial found less wrinkle depth and volume with a GHK-Cu serum, while a trial after laser treatment found no objective benefit. Reviews in 2026 call the human evidence limited.
Are GHK-Cu injections safe?
There are limited human safety data. The FDA lists injectable GHK-Cu among compounding substances that may present significant safety risks, including immune reactions linked to impurities and aggregation.
Sources
These are the documents this page relies on.
- Mokhtar J, Mohamad B, Haddad J, et al. The regenerative potential of GHK-Cu in aesthetic medicine. Aesthet Surg J. Published online 20 August 2026 (sjag169)Aesthetic Surgery Journal (PubMed 42619529)
- Rahman E, Webb WR. Mechanistic plausibility should not be conflated with clinical validation of glycyl-L-histidyl-L-lysine-copper. Aesthet Surg J. Published online 4 November 2026 (sjag227)Aesthetic Surgery Journal (PubMed 42981269)
- Mokhtar J, Lellouch AG. Response to: Mechanistic plausibility should not be conflated with clinical validation of GHK-Cu. Aesthet Surg J. Published online 10 November 2026 (sjag248)Aesthetic Surgery Journal (PubMed 43006658)
- Badenhorst T, Svirskis D, Merrilees M, Bolke L, Wu Z. Effects of GHK-Cu on MMP and TIMP expression, collagen and elastin production, and facial wrinkle parameters. J Aging Sci. 2016;4(3):166Journal of Aging Science
- Miller TR, Wagner JD, Baack BR, Eisbach KJ. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006;8(4):252-259Archives of Facial Plastic Surgery (PubMed 16847171)
- Najafi N, Maatouk H, Vardanyan KG, Vartanian KB, Agrawal DK. A systematic review of the mechanisms and therapeutic applications of GHK-Cu in topical microneedle delivery: a case for expanded clinical trials. Arch Intern Med Res. 2026;9(3):269-293Archives of Internal Medicine Research (PubMed 42787770, PMC13604022)
- Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987International Journal of Molecular Sciences (PubMed 29986520)
- Joerg L, Zafar K, Jagdeo J. Peptides for hair growth and treatment of hair loss and alopecia: a systematic review. J Drugs Dermatol. 2026;25(11):1026-1032Journal of Drugs in Dermatology (PubMed 42976838)
- Certain bulk drug substances for use in compounding that may present significant safety risksUS Food and Drug Administration
- Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances (Federal Register notice, 30 October 2026)US Department of Health and Human Services
- Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances (policy document, Appendix A)US Department of Health and Human Services
- Mendias CL, Awan TM. Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance. Sports Med. 2026;56(8):1921-1935Sports Medicine (PubMed 41966639)
- Peptide products: public informationSAHPRA